Truist reiterates Eli Lilly stock rating on obesity drug approval By Investing.com

Truist reiterated a Buy and $1,281 price target on Eli Lilly after FDA approval of oral obesity drug Foundayo; Lilly has a market cap of $872B and reported 45% revenue growth over the last 12 months. Foundayo pricing: $25/month with commercial insurance (LillyDirect), $149/month self-pay, Medicare expected $50/month starting July 1, 2026; Truist forecasts $1.2B in 2026 sales (consensus $1.5B) and peak U.S. sales of $26B in 2036 (consensus $14B). Lilly also announced a potential $7.8B acquisition of Centessa Pharmaceuticals and received positive analyst reaffirmations from Barclays and BMO, supporting a bullish view on the stock.

Analysis

Lilly is structurally advantaged by a lower-friction oral obesity franchise that will re-shape payer negotiations, COGS allocation and prescriber workflows. Expect material second-order demand shifting away from high-touch injectable channels (impacts on specialty pharmacy margins, cold-chain logistics and injectables CMOs) and toward high-volume tablet CMOs and retail pharmacy dispensing; this reallocation favors firms with scalable tablet capacity and compresses per-patient service revenues at specialty providers.

Key near-term catalysts are real-world adherence, formulary placement cycles and the speed of national payer rule changes — each operates on different cadences (weeks for pharmacy networks, quarters for commercial formularies, and 6–18 months for full government program uptake). Major downside catalysts include rapid competitive repricing, safety signals in broader populations, or manufacturing yield issues that force temporary supply constraints; any of these can flip consensus ramp assumptions within a single quarter.

From a multi-year perspective, M&A and pipeline optionality become material: adding neuroscience assets increases leverage to non-metabolic franchises where valuation multiple expansion is possible, but integration and milestone delivery are binary outcomes that concentrate risk. The consensus optimism on durable peak share looks plausible only if price stability and payer generosity persist; if payers push utilization management or require step therapy, realized peak sales and margin profiles will be meaningfully lower than headline models suggest.

Tactically, the market likely misprices the interaction between high-volume oral demand and gross-margin mix; that creates opportunities to harvest accelerated equity upside while protecting against payer/regulatory reversals. Monitor PBM contracting windows and CMO capacity announcements as high-signal, short-horizon triggers that will change the risk/reward faster than clinical readouts.

Key Decisions for Investors

• Long LLY equity sized 2–4% of thematic healthcare sleeve, entry on any >5% pullback, target 12–18% upside over 6–12 months; hedge downside by buying 9–12 month LLY 10–15% OTM protective puts (~cost = 1–2% premium) to cap drawdown to ~15–20%.
• Buy CNTA (small biotech exposure) as a binary, event-driven leg: allocate 0.5–1% with a 6–12 month horizon to capture integration/milestone optionality; set 40–50% stop-loss and take-profit at 100% if milestone news confirms pipeline de-risking.
• Pair trade for payer-risk protection: long LLY (core) and short a high-multiple injectable leader (size the short at 30–50% of long notional) over 3–9 months — expected payoff if payer formulary shifts favor cheaper oral options; unwind if PBMs publish permissive class placement.
• Options trade: buy LLY 6–9 month call spreads (debit) to capture upside while limiting theta; simultaneously sell nearer-term calls around major PBM/formulary windows to finance position — target net 2–3x upside vs max loss and adjust if material supply or safety headlines occur.